Quanterix Corporation operates as an advanced life sciences and diagnostic instrumentation enterprise specializing in the development and commercialization of ultra-sensitive biomarker detection technologies. The company is classified within the biotechnology and medical research tools sector, focusing on empowering scientific researchers, pharmaceutical developers, and clinical laboratories to measure protein biomarkers at unprecedented lower limits than previously possible. By leveraging its proprietary Single Molecule Array (Simoa) platform, the firm bridges the gap between basic medical research and clinical diagnostic applications, enabling the early detection and tracking of complex diseases.